Arcutis Biotherapeutics Inc
For the period ended Mar 31, 2025. Filed May 6, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 6, 2025
ARQT$27.39+4.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(In thousands)
| Three Months Ended March 31, | ||
|---|---|---|
| 2025 | 2024 | |
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||
| Net loss | $(25,060) | $(35,382) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation | 153 | 170 |
| Non-cash lease expense | 111 | 97 |
| Amortization of intangible assets | 2,979 | 188 |
| Net accretion on marketable securities | (859) | (1,725) |
| Non-cash interest expense | 415 | 1,004 |
| Stock-based compensation expense | 9,778 | 10,030 |
| Changes in fair value of embedded derivative instrument | (210) | (543) |
| Changes in operating assets and liabilities: | ||
| Accounts receivable, net | (12,349) | (11,347) |
| Inventories | (1,951) | (113) |
| Prepaid expenses and other current assets | (3,282) | 5,538 |
| Accounts payable | 309 | 992 |
| Accrued liabilities | (214) | (332) |
| Operating lease liabilities | (200) | (180) |
| Net cash used in operating activities | (30,380) | (31,603) |
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||
| Purchases of marketable securities | (56,110) | (105,952) |
| Proceeds from maturities of marketable securities | 68,468 | 77,255 |
| Purchases of property and equipment | (608) | — |
| Net cash provided by (used in) investing activities | 11,750 | (28,697) |
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||
| Proceeds from issuance of common stock upon exercise of stock options | 395 | 82 |
| Proceeds from issuance of common stock, net of issuance costs | — | 161,682 |
| Net cash provided by financing activities | 395 | 161,764 |
| Effect of exchange rate changes on cash | 4 | (73) |
| Net (decrease) increase in cash, cash equivalents, and restricted cash | (18,231) | 101,391 |
| Cash, cash equivalents, and restricted cash at beginning of period | 71,952 | 89,323 |
| Cash, cash equivalents, and restricted cash at end of period | $53,721 | $190,714 |
| SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING INFORMATION: | ||
| Milestone for intangible asset not yet paid in cash | $10,000 | $— |
| SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION: | ||
| Interest expense paid in cash | $2,568 | $6,512 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.